NVCR News and Press, NovoCure Limited From 07/17/20

The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...

Novocure (NASDAQ: NVCR ) will collaborate with Merck (NYSE: MRK ) on a Phase 2 pilot study evaluating the concomitant use of Tumor Treating Fields and Keytruda (pembrolizumab) in PD-L1-positive non-small cell lung cancer (NSCLC) patients in a first-line setting. More news on: NovoCur...

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatmen...

Apellis Reports Completion of Enrollment for Two Phase 3 Studies Apellis Pharmaceuticals Inc. ( APLS ) reported that it has completed enrollment for two of its Phase 3 studies which are DERBY and OAKS. Both the studies are designed to evaluate intravitreal pegcetacoplan for treating geog...

I'm a picky investor. I buy only the highest-quality growth stocks I can find. I look for companies that are rapidly improving their financial statements, boast a strong competitive position, have a huge growth runway ahead of them, and are trading at an attractive valuation. I believe Novo...

The last patient has been enrolled in Novocure's (NASDAQ: NVCR ) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months. More news on: NovoCure Limited, Healt...

Final data collection will occur in six months Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and...

Novocure (NASDAQ: NVCR ) has launched MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave o...